Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3051% above fair value
$68.67−0.01 (-0.01%)
Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma net income
Net income is the profit left for shareholders after every expense, interest and tax.
Royalty Pharma's net income for the twelve months ending Jun 30, 2026 was $815.00M, down 20.4% year over year. For fiscal 2025 it was $770.95M, down 10.2% from the year before. The highest annual figure on record is $2.35B in fiscal 2019.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $770.95M | -10.2% |
| FY2024 | Dec 31, 2024 | $858.98M | -24.3% |
| FY2023 | Dec 31, 2023 | $1.13B | +2549.5% |
| FY2022 | Dec 31, 2022 | $42.83M | -93.1% |
| FY2021 | Dec 31, 2021 | $619.73M | -36.4% |
| FY2020 | Dec 31, 2020 | $975.04M | -58.5% |
| FY2019 | Dec 31, 2019 | $2.35B | +70.5% |
| FY2018 | Dec 31, 2018 | $1.38B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.88M | -44.4% |
| Q1 FY2026 | Mar 31, 2026 | $294.69M | +23.1% |
| Q4 FY2025 | Dec 31, 2025 | $214.21M | +2.9% |
| Q3 FY2025 | Sep 30, 2025 | $288.22M | -47.0% |
| Q2 FY2025 | Jun 30, 2025 | $32.18M | -68.5% |
| Q1 FY2025 | Mar 31, 2025 | $239.35M | +4909.4% |
| Q4 FY2024 | Dec 31, 2024 | $208.21M | -57.9% |
| Q3 FY2024 | Sep 30, 2024 | $543.99M | +654.3% |
| Q2 FY2024 | Jun 30, 2024 | $102.00M | -55.2% |
| Q1 FY2024 | Mar 31, 2024 | $4.78M | -98.6% |
| Q4 FY2023 | Dec 31, 2023 | $494.34M | – |
| Q3 FY2023 | Sep 30, 2023 | $72.11M | -49.4% |
| Q2 FY2023 | Jun 30, 2023 | $227.63M | -25.2% |
| Q1 FY2023 | Mar 31, 2023 | $340.76M | +558.3% |
| Q4 FY2022 | Dec 31, 2022 | -$456.08M | -5870.3% |
| Q3 FY2022 | Sep 30, 2022 | $142.65M | +40.0% |
| Q2 FY2022 | Jun 30, 2022 | $304.50M | -30.9% |
| Q1 FY2022 | Mar 31, 2022 | $51.76M | -25.1% |
| Q4 FY2021 | Dec 31, 2021 | $7.90M | -95.4% |
| Q3 FY2021 | Sep 30, 2021 | $101.93M | -64.9% |
| Q2 FY2021 | Jun 30, 2021 | $440.78M | -0.3% |
| Q1 FY2021 | Mar 31, 2021 | $69.12M | -3.0% |
| Q4 FY2020 | Dec 31, 2020 | $171.09M | -88.0% |
| Q3 FY2020 | Sep 30, 2020 | $290.63M | -28.9% |
| Q2 FY2020 | Jun 30, 2020 | $442.07M | +191.4% |
| Q1 FY2020 | Mar 31, 2020 | $71.24M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.42B | – |
| Q3 FY2019 | Sep 30, 2019 | $408.98M | – |
| Q2 FY2019 | Jun 30, 2019 | $151.71M | – |
See a number that looks wrong?